This international registry provides the largest real-world signal that neurohormonal therapy, even a single agent, is associated with survival benefit after durable LVAD implantation.
📅 Journal publication: Jul 4, 2026·Last updated: Oct 5, 2026
GDMT boosts survival in LVAD patients, but why so underused?
Guideline-directed medical therapy (GDMT) is recommended for left ventricular assist device (LVAD) recipients, yet its real-world impact needs clarity. The study showed that GDMT was associated with improved survival in LVAD patients, with triple therapy reducing all-cause mortality by 49% and also lowering late ventricular arrhythmias. While GDMT improves outcomes, only 30% of patients received all recommended therapies, indicating a need for better implementation in LVAD care. GDMT significantly enhances survival in LVAD patients, but uptake remains low.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Cherbi M, Delmas C, Gautier P, Benali K, Bode K, Efimova E, Dashkevich A, Liang J, Larson J, Mondesert B, Boulet J, Noly PE, Picard F, Pasquié JL, Gourraud JB, Ninni S, Jesel L, Sebestyen A, Para M, Deharo JC, Anselme F, Champ-Rigot L, M'Rabet S, Pierre B, Eschalier R, Echivard M, Martin AC, Lellouche N, Pozzi M, Groussin P, Flecher E, Galand V, Martins R
Citation:Cherbi M, Delmas C, Gautier P, et al. Clinical impact of guideline-directed medical therapy in patients with left ventricular assist device: an international multicentre study. ESC heart failure. 2026;13(4). doi:10.1093/eschf/xvag174